Genetic education, risk assessment, and testing can save lives by facilitating the identification of pathogenic germline variants (PGVs) in cancer-susceptibility genes. PGVs are identified in approximately 13% of cancer diagnoses across all tumor types in the United States.1 Although PGVs in genes associated with cancer predisposition occur in individuals of all racial/ethnic backgrounds, 67% of cancer-related genome-wide association studies focus on European populations.2